Yeah ... at what point does the "vast ocean" of potential health benefits (and safety) just rise up and break through the "dam" of ineptitude in leadership holding it back?! 

Whether Apabetalone is ultimately "all that" or not, this compound (and library) deserves prompt exploration & study, toward answers, rather than collecting dust and losing extremely valuable patent years.

Sad, for investors and sick patients alike. A case study in great science, coupled with management futility.